<DOC>
	<DOCNO>NCT02429271</DOCNO>
	<brief_summary>This prospective randomized study , investigate coronary microvascular function assess coronary angiography administration ticagrelor compare clopidogrel patient myocardial infarction ST segment elevation thrombolysis .</brief_summary>
	<brief_title>A Multicenter Trial Assess MIcrovascular Integrity Left Ventricular Function Recovery After Clopidogrel TicagrelOr Administration , Patients With STEMI Treated With Thrombolysis - The 'MIRTOS ' Study</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure . 2 . Male female subject , 1875 year age ( inclusive ) . 3 . STEMI eligible thrombolysis 4 . Inability perform primary PCI , transport time center carry primary PCI last two hour 5 . Ability transportation 324 hour thrombolysis order perform coronary angiography PCI . This period may extend reason extreme importance 72 hour late . 1 . Inability give inform consent . 2 . Pretreatment inhibitor purinergic receptor P2Y , Gprotein couple , 12 ( P2Y12 ) within 7day period prior randomization . 3 . Cardiogenic shock accord Killip classification class 4 . 4 . Suspicion evidence mechanical complication , include mitral valve dysfunction , ventricular septal rupture , rupture leave ventricle . 5 . Current use warfarin anticoagulant drug . 6 . Known multivessel coronary artery disease suitable revascularization . 7 . Any contraindication thrombolytic therapy Central nervous system damage neoplasms atrioventricular malformation Recent major trauma/surgery/head injury ( within precede 3 week ) Gastrointestinal bleeding within past month Known bleeding disorder ( exclude menses ) Aortic dissection Noncompressible puncture past 24 hour ( e.g . liver biopsy , lumbar puncture ) . 8 . Other bleed diathesis , consider Investigator high risk bleeding . 9 . Any kind stroke past year haemorrhagic stroke ever . 10 . Severe uncontrolled hypertension ( &gt; 180/110 mmHg ) prior randomisation . 11 . Prolonged traumatic cardiopulmonary resuscitation ( &gt; 10 minute ) last 2 week . 12 . Known thrombocytopenia define platelet count &lt; 100,000/mm3 . 13 . Known anemia ( hemoglobin [ Hb ] &lt; 10 gr/dL ) . 14 . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . 15 . Chronic dialysis know chronic renal failure ( glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73m2 ) . 16 . Known moderate severe hepatic impairment . 17 . Severe uncontrolled chronic obstructive pulmonary disease . 18 . Concomitant use potent Cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin voriconazole , grapefruit juice 1 litre daily ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , inducer ( carbamazepine , dexamethasone , phenobarbital , phenytoin , rifampin , rifapentine ) . 19 . Concomitant use drug metabolize cytochrome P450 , family 2 , subfamily C , polypeptide 19 ( CYP2C19 ) ( omeprazole esomeprazole , fluvoxamine , fluoxetine , moclobemide , voriconazole , fluconazole , ticlopidine , ciprofloxacin , cimetidine , carbamazepine , oxcarbazepine chloramphenicol ) . 20 . Increased risk bradycardic event ( e.g . know sick sinus syndrome third degree atrioventricular ( AV ) block previous document syncope suspect due bradycardia unless treat pacemaker ) . 21 . Any known contraindication clopidogrel , Acetylsalicylic Acid ( ASA ) , ticagrelor . 22 . Current pregnancy , active lactation parturition ( childbirth ) within previous 30 day ; woman childbearing potential must negative urine pregnancy test , use medically accept method birth control . 23 . Treatment investigational agent ( include placebo ) device within 30 day prior randomization plan use investigational agent device prior completion study participation . 24 . Any noncardiac condition life expectancy le 1 year . 25 . Inability adhere followup requirement reason condition investigator feel would place patient increase risk investigational therapy initiate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>undergoing thrombolysis</keyword>
</DOC>